Now that J&J has wrapped up the $1 billion acquisition of Aragon and its next-gen treatment for castration-resistant prostate cancer, the biotech's founders can devote themselves to a new startup that now has a $30 million venture bankroll to work with.
Bioinformatics startup InterpretOmics has snagged $1.6 million (Rs 10 crore) from a slate of angel backers, seeking to grow its business of providing cloud-based software for analyzing genomics data, the company said last week. The only named investor was the Singapore-based shipping company Amarante.
Less than a year since launching, Arpeggi has agreed to be acquired by the 13-year-old DNA testing outfit Gene by Gene. And the genome analysis software from Austin-based Arpeggi is expected to propel the Houston buyer's plans to offer affordable genomic testing and diagnostics services for the consumer and healthcare markets.
Bina Technologies just received some capital from the tech world to bolster its DNA data analysis platform. Jerry Yang, the co-founder and former CEO of Yahoo ($YHOO), has backed Redwood City, CA-based Bina through his venture outfit, AME Cloud Ventures.
Global consulting firm InVentiv Health has struck a partnership with the social analytics startup Medikly, believing that young company's technology gives it an edge in assisting its clients with finding physicians to participate in clinical research.
The endorsement comes as San Francisco-based Rock Health announces a new class of 11 startups for its accelerator program, which provides access to guidance, financing and experts to help the young operations succeed.
Protagonist Therapeutics has found another major corporate investor to support its pursuit of new peptide drugs. Johnson & Johnson Development Corporation, a unit of J&J, led the Menlo Park, CA-based biotech group's $14 million Series B financing, and Eli Lilly's Lilly Ventures and Starfish Ventures returned for the latest round of funding after previously investing in Protagonist.
Investors have activated a new "crowdfunding" website for life sciences deals. Dubbed VentureHealth, the website aims to expand the number of deep-pocketed players who are actively investing in medical technology startups as some traditional sources wilt.
To translate Big Data in genomics into useful healthcare products, entrepreneurs might have roll up their sleeves and invent their own solutions like the Srinivasan brothers have.
The London-based drug giant has partnered with veteran life sciences investors at Avalon Ventures to bankroll a crop of drug-hunting startups in San Diego, with GSK committing the bulk of the alliance's $495 million to fuel the new companies.